Recursion Pharmaceuticals ($RXRX) Announces Positive Phase 2 Results for REC-994 in CCM

Sep 3, 2024, 12:08 PM

Recursion Pharmaceuticals ($RXRX) has announced positive Phase 2 topline results for REC-994, a first-in-disease investigational treatment for symptomatic cerebral cavernous malformation (CCM). The drug met its primary endpoint of safety and tolerability. Additionally, magnetic resonance imaging (MRI)-based secondary efficacy endpoints showed a trend towards reduced lesion volume. Despite these promising results, some investors remain cautious about the AI drug discovery developer's future prospects.